193 related articles for article (PubMed ID: 35982173)
1. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
Minegishi Y; Kiyotani K; Nemoto K; Inoue Y; Haga Y; Fujii R; Saichi N; Nagayama S; Ueda K
Commun Biol; 2022 Aug; 5(1):831. PubMed ID: 35982173
[TBL] [Abstract][Full Text] [Related]
2. Targeted Mass Spectrometry Analyses of Somatic Mutations in Colorectal Cancer Specimens Using Differential Ion Mobility.
Wu Z; Bonneil É; Belford M; Boeser C; Dunyach JJ; Thibault P
J Proteome Res; 2024 Feb; 23(2):644-652. PubMed ID: 38153093
[TBL] [Abstract][Full Text] [Related]
3. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
4. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
[TBL] [Abstract][Full Text] [Related]
5. Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.
Klaeger S; Apffel A; Clauser KR; Sarkizova S; Oliveira G; Rachimi S; Le PM; Tarren A; Chea V; Abelin JG; Braun DA; Ott PA; Keshishian H; Hacohen N; Keskin DB; Wu CJ; Carr SA
Mol Cell Proteomics; 2021; 20():100133. PubMed ID: 34391888
[TBL] [Abstract][Full Text] [Related]
6. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
Minegishi Y; Haga Y; Ueda K
Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
[TBL] [Abstract][Full Text] [Related]
7. Sensitive, High-Throughput HLA-I and HLA-II Immunopeptidomics Using Parallel Accumulation-Serial Fragmentation Mass Spectrometry.
Phulphagar KM; Ctortecka C; Jacome ASV; Klaeger S; Verzani EK; Hernandez GM; Udeshi ND; Clauser KR; Abelin JG; Carr SA
Mol Cell Proteomics; 2023 Jun; 22(6):100563. PubMed ID: 37142057
[TBL] [Abstract][Full Text] [Related]
8. TOF
Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
Pharmacol Res; 2024 May; 204():107209. PubMed ID: 38740147
[TBL] [Abstract][Full Text] [Related]
10. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
11. Accurate Quantitative Proteomic Analyses Using Metabolic Labeling and High Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS).
Pfammatter S; Bonneil E; McManus FP; Thibault P
J Proteome Res; 2019 May; 18(5):2129-2138. PubMed ID: 30919622
[TBL] [Abstract][Full Text] [Related]
12. The addition of FAIMS increases targeted proteomics sensitivity from FFPE tumor biopsies.
Sweet S; Chain D; Yu W; Martin P; Rebelatto M; Chambers A; Cecchi F; Kim YJ
Sci Rep; 2022 Aug; 12(1):13876. PubMed ID: 35974054
[TBL] [Abstract][Full Text] [Related]
13. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
ElAbd H; Franke A
Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
[TBL] [Abstract][Full Text] [Related]
14. IMBAS-MS Discovers Organ-Specific HLA Peptide Patterns in Plasma.
Wahle M; Thielert M; Zwiebel M; Skowronek P; Zeng WF; Mann M
Mol Cell Proteomics; 2024 Jan; 23(1):100689. PubMed ID: 38043703
[TBL] [Abstract][Full Text] [Related]
15. Expanding the Depth and Sensitivity of Cross-Link Identification by Differential Ion Mobility Using High-Field Asymmetric Waveform Ion Mobility Spectrometry.
Schnirch L; Nadler-Holly M; Siao SW; Frese CK; Viner R; Liu F
Anal Chem; 2020 Aug; 92(15):10495-10503. PubMed ID: 32643919
[TBL] [Abstract][Full Text] [Related]
16. The measurement of KRAS G12 mutants using multiplexed selected reaction monitoring and ion mobility mass spectrometry.
Norman RL; Singh R; Langridge JI; Ng LL; Jones DJL
Rapid Commun Mass Spectrom; 2020 Sep; 34 Suppl 4(Suppl 4):e8657. PubMed ID: 31800120
[TBL] [Abstract][Full Text] [Related]
17. High-field asymmetric waveform ion mobility spectrometry for mass spectrometry-based proteomics.
Swearingen KE; Moritz RL
Expert Rev Proteomics; 2012 Oct; 9(5):505-17. PubMed ID: 23194268
[TBL] [Abstract][Full Text] [Related]
18. High Field Asymmetric Waveform Ion Mobility Spectrometry in Nontargeted Bottom-up Proteomics of Dried Blood Spots.
Rosting C; Yu J; Cooper HJ
J Proteome Res; 2018 Jun; 17(6):1997-2004. PubMed ID: 29707944
[TBL] [Abstract][Full Text] [Related]
19. 'Hotspots' of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization.
Müller M; Gfeller D; Coukos G; Bassani-Sternberg M
Front Immunol; 2017; 8():1367. PubMed ID: 29104575
[TBL] [Abstract][Full Text] [Related]
20. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
